Diagnostic test quality may not be something that many drug makers have a lot of experience dealing with, but shortfalls in a diagnostic development program can undercut efforts to streamline clinical trials for personalized medicines.
The need for a high-quality diagnostic test development program was a key message delivered by a representative from FDA’s device center at a Sept. 14 conference on drug/diagnostic co-development.